Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma

References

• Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, . Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115–24.
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, . AVOREN Trial investigators, bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007;70:2103–11.
   Google Scholar
• Escudier B, Kataja V, ESMO Guidelines Working Group Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20: 81–2.
   PubMed Web of Science ®Google Scholar
• Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, . Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909–18.
   PubMed Web of Science ®Google Scholar
• Bjornsti MA, Houghton PJ. The TOR pathway: A target for cancer therapy. Nat Rev Cancer 2004;4:335–48.
   PubMed Web of Science ®Google Scholar
• Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: Exploiting the hypoxia-induced pathway. Clin Cancer Res 2007;9:4641–52.
   Google Scholar
• Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, . Global ARCC Trial, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271–81.
   PubMed Web of Science ®Google Scholar
• Sablin MP, Negrier S, Ravaud A, Oudard S, Balleyguier C, Gautier J, . Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2009;182:29–34; discussion 34. Epub 2009 May 17.
   PubMed Web of Science ®Google Scholar
• Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009;115:61–7.
   PubMed Web of Science ®Google Scholar
• Hajdenberg J, Oberoi S, Cohen N, Kayaleh O, Harding D, Tseng J. Evaluation of VEGF targeted therapy efficacy in mRCC after sorafenib failure or intolerance [abstract]. In Proceedings of the American Society of Clinical Oncology 2007 Annual Meeting, Vol 25.
   Google Scholar
• Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, . RECORD-1 Study Group Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372:449–56. Epub 2008 Jul 22.
   PubMed Web of Science ®Google Scholar
• Wyeth CCI-404 (2007) Temsirolimus versus sorafenib as second-line therapy in patients with advanced RCC who have failed first-line sunitinib. This study is currently recruiting participants. Clinical Trials.gov Identifier: NCT00474786.
   Google Scholar
• Duffaud F, Therasse P. New guidelines to evaluate the response to treatment in solid tumors. Bull Cancer 2000; 87:881–6.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, . Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22:454–63.
   PubMed Web of Science ®Google Scholar
• Mackenzie MJ, Rini BI, Elson P, Schwandt A, Wood L, Trinkhaus M, . Temsirolimus in VEGF-refractory metastatic renal cell carcinoma. Ann Oncol 2011;22:145–8.
   PubMed Web of Science ®Google Scholar
• Gerullis H, Bergmann L, Maute L, Ecke TH, Eimer C, Bagner JW, . Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma. Med Oncol 2010;27:373–8.
   PubMed Web of Science ®Google Scholar
• Mahalingam D, Medina EC, Esquivel JA 2nd, Espitia CM, Smith CM, Oberheu K, . Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res 2010;16:141–53.
   PubMed Web of Science ®Google Scholar
• Merchan JR, Liu G, Fitch T, Picus J, Quin R, Pitot HC, . Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results [abstract]. In Proceedings of the American Society of Clinical Oncology 2007 Annual Meeting, Vol 25.
   Google Scholar
• Escudier BJ, Negrier S, Gravis G, Chevreau C, Delva R, Bay J, . Can the combination of temsirolimus and bevacizumab improve the treatment of metastaic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial [abstract]. In Proceedings of the American Society of Clinical Oncology 2010 Annual Meeting, Vol 28.
   Google Scholar
• Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, . Regulation of hypoxia-inducible factor 1 alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22:7004–14.
   PubMed Web of Science ®Google Scholar
• Turner KJ, Moore JW, Jones A, Taylor CF, Cuthbert-Heavens D, Han C, . Expression of hypoxia-inducible factors in human renal cancer: Relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 2002;62: 2957–61.
   PubMed Web of Science ®Google Scholar